Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
- Chia Jui Yen
- , Naomi Kiyota
- , Nobuhiro Hanai
- , Shunji Takahashi
- , Tomoya Yokota
- , Shigemichi Iwae
- , Yasushi Shimizu
- , Ruey Long Hong
- , Masahiro Goto
- , Jin Hyoung Kang
- , Wing Sum Kenneth Li
- , Robert L. Ferris
- , Maura Gillison
- , Toshimitsu Endo
- , Vijayvel Jayaprakash
- , Makoto Tahara
- National Cheng Kung University
- Kobe University
- Aichi Cancer Center Hospital and Research Institute
- Japanese Foundation for Cancer Research
- Shizuoka Cancer Center
- Hyogo Cancer Center
- Hokkaido University
- National Taiwan University
- Osaka Medical and Pharmaceutical University
- Queen Elizabeth Hospital Hong Kong
- University of Pittsburgh
- University of Texas MD Anderson Cancer Center
- Ono Pharmaceutical Co., Ltd.
- Bristol-Myers Squibb
- National Cancer Center Japan
Research output: Contribution to journal › Article › peer-review
33
Scopus
citations